UBS Group
TXMD icon

UBS Group’s TherapeuticsMD TXMD Stock Holding History

UBS Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$669 Sell
331
-783
-70% -$1.76K ﹤0.01% 9791
2025
Q4 		$1.81K Buy
1,114
+752
+208% +$1.09K ﹤0.01% 9463
2025
Q3 		$390 Sell
362
-4,140
-92% -$4.64K ﹤0.01% 9700
2025
Q2 		$5.22K Buy
4,502
+4,327
+2,473% +$5.24K ﹤0.01% 9195
2025
Q1 		$162 Sell
175
-1,837
-91% -$1.83K ﹤0.01% 9906
2024
Q4 		$1.73K Sell
2,012
-2,835
-58% -$3.99K ﹤0.01% 9171
2024
Q3 		$8.05K Sell
4,847
-4,269
-47% -$7.43K ﹤0.01% 7856
2024
Q2 		$14.7K Buy
9,116
+1,302
+17% +$2.63K ﹤0.01% 7500
2024
Q1 		$17.9K Buy
7,814
+6,542
+514% +$15.1K ﹤0.01% 6972
2023
Q4 		$2.86K Buy
1,272
+575
+82% +$1.39K ﹤0.01% 8045
2023
Q3 		$2.1K Sell
697
-1,675
-71% -$6.34K ﹤0.01% 7768
2023
Q2 		$9.77K Sell
2,372
-3,138
-57% -$12.3K ﹤0.01% 7164
2023
Q1 		$20.7K Buy
5,510
+5,194
+1,644% +$24.9K ﹤0.01% 7051
2022
Q4 		$1.77K Buy
316
+229
+263% +$1.35K ﹤0.01% 9798
2022
Q3 		$0 Sell
87
-18,046
-100% -$146K ﹤0.01% 10942
2022
Q2 		$180K Buy
18,133
+18,032
+17,853% +$172K ﹤0.01% 5010
2022
Q1 		$2K Sell
101
-305
-75% -$4.8K ﹤0.01% 9676
2021
Q4 		$7K Buy
406
+38
+10% +$1.14K ﹤0.01% 9167
2021
Q3 		$14K Sell
368
-320
-47% -$14.2K ﹤0.01% 7599
2021
Q2 		$41K Buy
688
+277
+67% +$16.8K ﹤0.01% 6619
2021
Q1 		$28K Sell
411
-215
-34% -$16.8K ﹤0.01% 7069
2020
Q4 		$37K Sell
626
-436
-41% -$29.8K ﹤0.01% 6461
2020
Q3 		$84K Sell
1,062
-903
-46% -$72K ﹤0.01% 5285
2020
Q2 		$123K Buy
1,965
+1,028
+110% +$59.9K ﹤0.01% 5140
2020
Q1 		$50K Buy
937
+58
+7% +$5.75K ﹤0.01% 5831
2019
Q4 		$107K Sell
879
-107
-11% -$15.4K ﹤0.01% 5964
2019
Q3 		$179K Buy
986
+128
+15% +$18K ﹤0.01% 5330
2019
Q2 		$112K Sell
858
-2,796
-77% -$501K ﹤0.01% 5304
2019
Q1 		$890K Buy
3,654
+2,164
+145% +$573K ﹤0.01% 3674
2018
Q4 		$284K Sell
1,490
-698
-32% -$170K ﹤0.01% 4674
2018
Q3 		$718K Buy
2,188
+1,178
+117% +$361K ﹤0.01% 4139
2018
Q2 		$315K Buy
1,010
+274
+37% +$83.7K ﹤0.01% 4661
2018
Q1 		$179K Buy
736
+107
+17% +$30K ﹤0.01% 4852
2017
Q4 		$190K Sell
629
-1
-0.2% -$278 ﹤0.01% 4940
2017
Q3 		$167K Sell
630
-45
-7% -$13K ﹤0.01% 4973
2017
Q2 		$178K Buy
675
+245
+57% +$61.4K ﹤0.01% 4811
2017
Q1 		$155K Sell
430
-23
-5% -$7.12K ﹤0.01% 4803
2016
Q4 		$131K Sell
453
-93
-17% -$28.8K ﹤0.01% 5101
2016
Q3 		$186K Sell
546
-49
-8% -$17.9K ﹤0.01% 4597
2016
Q2 		$252K Sell
595
-3,663
-86% -$1.51M ﹤0.01% 4392
2016
Q1 		$1.36M Buy
4,258
+110
+3% +$37.5K ﹤0.01% 3010
2015
Q4 		$2.15M Buy
4,148
+82
+2% +$30.3K ﹤0.01% 2721
2015
Q3 		$1.19M Sell
4,066
-94
-2% -$33.4K ﹤0.01% 3197
2015
Q2 		$1.63M Buy
4,160
+4,096
+6,400% +$1.45M ﹤0.01% 3170
2015
Q1 		$19K Sell
64
-149
-70% -$36.4K ﹤0.01% 7048
2014
Q4 		$47K Buy
+213
New +$43.9K ﹤0.01% 6558

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's TXMD Position: Q1 2026 in Review

UBS Group reduced its TherapeuticsMD (TXMD) stake by 70% in Q1 2026, selling an estimated $1.76K and leaving 331 shares worth $669. The position accounts for ﹤0.01% of the portfolio, ranked #9791.

UBS Group first reported a position in TXMD in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.15M in Q4 2015. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • UBS Group held 331 shares of TherapeuticsMD worth $669 as of Q1 2026.
  • UBS Group sold 783 TherapeuticsMD shares in Q1 2026, an estimated $1.76K.
  • TherapeuticsMD made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9791 holding.
  • UBS Group first reported a position in TherapeuticsMD in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's TherapeuticsMD position peaked at $2.15M in Q4 2015.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.